A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

Inclusion Criteria: * Reside in the United States * Be able to communicate and read fluently in English (U.S.) * Have received the RIV3 vaccine within the past 21 days * Have received the RIV3 vaccine in one of the 35 U.S. states or Washington, D.C., where the recruitment partner pharmacy operates * Be able to provide explicit informed consent to participate in the study * Be physically able to participate in a 30-min online survey using an internet-enabled device (e.g., computer, tablet, or smartphone) Exclusion Criteria: * Are unable to participate in the online survey * Have received any other vaccine within the two weeks preceding the study vaccine (RIV3 vaccination); i.e., there must be at least a 2-week interval between the last vaccination and the time of enrollment/study execution * Have received co-administered vaccinations on the same day as the study vaccine The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.